Skye Bioscience, Inc. — Company profile
Healthcare · Biotechnology · United States
Last price 1.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 5.80M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation. Nimacimab addresses metabolic processes related to energy expenditure, fat mobilization, leptin sensitivity, appetite regulation, and satiety signaling. Skye Bioscience, Inc. was formerly known as Emerald Bioscience Inc. and changed its name to Skye Bioscience, Inc. in December 2020. Skye Bioscience, Inc. was incorporated in 2011 and is based in San Diego, California.
Details
| Name | Skye Bioscience, Inc. |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 2 |
| Founded | 2012 |
| Ceo | Punit Dhillon |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US83086J3095 |
| Cusip | 83086J309 |
| Cik | 1516551 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Punit S. Dhillon B.A. | President, Chief Executive Officer, Principal Financial and Accounting Officer & Director |
Contact
| Address | 11250 El Camino Real, Suite 100, San Diego, California 92130, United States |
| Phone | 858 410 0266 |
| Website | https://skyebioscience.com |